SUPRAME: what clinicians are saying
anzutresgene autoleucel (IMA203) in previously treated, unresectable or metastatic cutaneous melanoma · NCT06743126 ↗ · Phase 3 · Immatics US, Inc.
For SUPRAME, the clinicians cited see potential to change care based on earlier response activity, but comparative benefit remains unproven. One physician sees a possible option for some patients unsuitable for lifileucel, dependent on HLA matching and future approval. A physician described in the sources as presenting the trial cautions that treatment remains intensive despite avoiding surgery. Comparative safety remains uncertain, and differing descriptions of interleukin support remain unresolved.
Created with AI · how we check it
- edition 1
- commentary checked Nov 20, 2026
- 108 verified statements
This edition $750, with MCP access for your AI agent. Get this report
10 findings, and what sits behind each
01. Phase 1 IMA203: what most speakers highlight in PD-1-refractory melanoma response rates
5 of the report's 9 cited clinicians · 25 statements from 8 speakers in 18 sources, 6 of them podcasts or videos · 20 passages
Limitations recorded: 3.
Draws on: Safety and tolerability, Secondary endpoints, The comparison, Population and setting, Primary endpoint: Progression-free survival assessed by BICR, Design and conduct.
02. IMA203 vs TIL: some clinicians value no surgery; one flags therapy intensity
2 of the report's 9 cited clinicians · 17 statements from 4 speakers in 8 sources, 5 of them podcasts or videos · 11 passages
Limitations recorded: 2.
Draws on: The comparison, Safety and tolerability, Secondary endpoints, Design and conduct.
03. Phase 1 IMA203 safety: where speakers split on the toxicity burden
2 of the report's 9 cited clinicians · 10 statements from 4 speakers in 8 sources, 5 of them podcasts or videos · 9 passages
Limitations recorded: 4.
Draws on: Safety and tolerability, The comparison, Secondary endpoints, Population and setting.
04. IMA203 access: why most speakers stress HLA matching
3 of the report's 9 cited clinicians · 13 statements from 5 speakers in 9 sources, 5 of them podcasts or videos · 12 passages
Limitations recorded: 3.
Draws on: Population and setting, The comparison, Design and conduct.
05. Cell therapy: what speakers say
1 of the report's 9 cited clinicians · 5 statements from 1 speaker in 2 sources, all podcasts or videos · 3 passages
Limitations recorded: 2.
Draws on: Population and setting, Safety and tolerability.
06. SUPRAME: why clinicians value randomization; one frames it as TCR vs TIL
3 of the report's 9 cited clinicians · 12 statements from 3 speakers in 7 sources, 6 of them podcasts or videos · 9 passages
Limitations recorded: 3.
Draws on: Design and conduct, Population and setting, The comparison, Primary endpoint: Progression-free survival assessed by BICR, Secondary endpoints.
07. Cell therapy: what speakers say
4 of the report's 9 cited clinicians · 14 statements from 5 speakers in 14 sources, 3 of them podcasts or videos · 14 passages
Limitations recorded: 2.
Draws on: Design and conduct, Population and setting.
08. SUPRAME: what speakers say
No named clinician · accounts and unnamed speakers · 12 statements from 2 speakers in 7 sources · 9 passages
Limitations recorded: 3.
Draws on: Design and conduct, Primary endpoint: Progression-free survival assessed by BICR, Population and setting.
09. SUPRAME: what speakers say
No named clinician · accounts and unnamed speakers · 10 statements in 7 sources · 8 passages
Limitations recorded: 4.
Draws on: Secondary endpoints, The comparison, Safety and tolerability.
Beyond the trial population
10. PRAME-directed TCR-T: some clinicians consider broader solid-tumor use possible
4 of the report's 9 cited clinicians · 7 statements from 4 speakers in 5 sources, 3 of them podcasts or videos · 5 passages
Limitations recorded: 2.
Counts overlap, since one statement can back several findings. They show what the report kept, not how many clinicians agree. The full report includes the interpretations and source links.
Select a finding to see what the full report holds for it. Select a part of the trial to see which findings draw on it.
- Finding 1 of 10
5 of the report's 9 cited clinicians
Phase 1 IMA203: what most speakers highlight in PD-1-refractory melanoma response rates
25 statements from 8 speakers in 18 sources, 6 of them podcasts or videos
7 of the 8 named speakers in this finding hold this view
- 25
- statements
- 20
- passages
- 18
- sources
- 8
- speakers
What the statements areViews 16Questions and uncertainty 0Clinical experience 0Comparisons 3Restated results and context 6Statement-to-passage links (a passage can back several statements)Supporting a statement 25Giving context 2Recorded with the findingLimitations: 3
12 posts and articles · 6 podcasts and video
Draws on: Safety and tolerability, Secondary endpoints, The comparison, Population and setting, Primary endpoint: Progression-free survival assessed by BICR, Design and conduct.
- Beyond the trial population
Thicker lines mean more shared statements. A finding without a line goes beyond the registered design. Counts overlap: one statement can back several findings.
1 of the 10 findings and 5 of the 108 statements are about other patients, lines of treatment or settings. The report lists them after the trial findings under “Beyond the trial population”, as this page does.
Physician · US
Podcast · Jan 2026
NPI checked · finding 1
A physician identifies the SUPRAME trial as one of the trials generating the most excitement.
Statements as the report records them, by the speaker's role only. Full statements, speaker names and links to each source are in the report.
Abbreviations (4)
BICR, blinded independent central review; HCP, healthcare professional; MCP, Model Context Protocol, how AI agents read the report; NPI, National Provider Identifier, the US registry number for clinicians.
The full SUPRAME report gives each finding its interpretation, the attributed views behind it, counterviews, limits and the verified statements, each linked to the original. One report in the catalog, IDeate-Lung01, is free in full, so you can see what a paid report holds before you buy: read the free IDeate-Lung01 report.
What do clinicians need SUPRAME to show on progression-free survival versus investigator's choice before using IMA203 as standard care for HLA-A*02:01-positive, PD-1-refractory unresectable or metastatic cutaneous melanoma?
From findings F1 (25 statements from 8 speakers in 18 sources) and F6 (12 statements from 3 speakers in 7 sources). The report shows what clinicians said and the sources behind it; it does not settle the question.
By the numbers
- 66commentary sources screened
- 39sources cited by verified statements
- 16named in screened sources
- 16speakers cited in the report
- 10cited speakers with a verified identity
9 cited clinicians, speakers with a confirmed clinical role, of them 9 physicians. By role and specialty:
- 4 physician, specialty not confirmed
- 4 physician, Medical oncology
- 1 physician, Hematology and oncology
Also in the sources: 9 organizational or shared accounts, not counted as people.
- 108verified statements, each linked to its source
- 56of them from speakers with a confirmed clinical role
- 10findings
Built by AI from public clinician commentary, checked by automated review; every statement links to its source.
A cited clinician is a cited speaker whose clinical role the NPI registry or their own institution's staff page confirms; a role a source only states is not counted. A verified identity says who a speaker is, with or without such a role. Physicians are clinicians whose confirmed role is a physician's.
Counts show what the report kept, not how many clinicians hold a view. Size is set by the verified statements; Standard and Deep need 5 or more cited clinicians. Statements from sponsors, hosts and organisations are labelled and count apart.
What's inside
| Section | Items | Access |
|---|---|---|
| Findings with interpretation, counterviews and limits | 10 | Titles free |
| Detailed analysis | 12 sections | Paid |
| Verified statements with short source quotes and links | 108 | Paid |
| Who said each statement: the cited speakers | 16 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 9 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 10 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 12 | Free |
| Sources with links | 39 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |
Every edition names who said each statement, with MCP access for your AI agent. Each verified speaker comes with their verified IDs (NPI, ORCID, staff page) so your team can check each attribution. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
Trial aspects
12 discussed · 0 no commentary found · 0 assessment incomplete| Aspect | Statements | Sources |
|---|---|---|
| Primary endpoint: Progression-free survival assessed by BICR | 7 | 7 |
| Secondary endpoints | 6 | 5 |
| Population and setting | 17 | 11 |
| The comparisonThe registered arms and what clinicians said about how they compare. | 21 | 8 |
| Safety and tolerability | 11 | 9 |
| Design and conduct | 18 | 14 |
| HLA and PRAME work-up | 11 | 7 |
| Sequencing, progression monitoring and trial referral | 12 | 8 |
| Manufacturing, administration and service readiness | 13 | 8 |
| Earlier IMA203 phase 1/1b evidence and its relevance to SUPRAME expectations | 18 | 17 |
| Secondary-source forecasts and competing-development benchmarks | 16 | 12 |
| Potential PRAME platform beyond melanoma | 6 | 5 |
Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.
Sources
108 verified statements from 39 cited sources. A video or podcast is one source but often carries many statements, so the table counts statements, not just posts.
| Channel | Statements | Cited | Screened | |
|---|---|---|---|---|
| Video & audio · 53 statements · 49% | ||||
| YouTube | 22 | 3 | 4 | |
| Podcasts | 31 | 3 | 3 | |
| Posts · 55 statements · 51% | ||||
| X threads | 46 | 24 | 47 | |
| LinkedIn posts | 5 | 5 | 5 | |
| Bluesky threads | 4 | 4 | 7 | |
Screened: found and read for this trial. Cited: backs at least one statement. Bar = statements; a statement drawn from two sources counts half to each. How we sourced and checked this
max 16 / quarter
- Screened window
- Oct 10, 2024 → Oct 30, 2026
- Cited window
- Oct 11, 2024 → Oct 30, 2026
- Retrieved
- Nov 20, 2026
The trial
from ClinicalTrials.gov- Title
- A Prospective, Multicenter, Open-label, Randomized, Actively Controlled, Parallel-group Phase 3 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of IMA203 Versus Investigator's Choice of Treatment in Patients With Previously Treated, Unresectable or Metastatic Cutaneous Melanoma (ACTengine® IMA203-301)
- Registry
- NCT06743126
- Study IDs
- IMA203-301
- Sponsor
- Immatics US, Inc.
- Design
- Phase 3 · Interventional, randomized, parallel
- Status
- Recruiting
- Enrollment
- 450 estimated
- Registered
- 2024-12-19
- Start
- 2025-01-14 actual
- Primary completion
- 2028-01 estimated
- Primary endpoint
- Progression-free survival assessed by BICR
- Interventions
- 11 registered
More on: Melanoma
Scope and limits
This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.
- Discussion that does not name the trial may be missing from this edition.
- Not yet captured in this edition: a view on enthusiasm for the investigational cell therapy and enrollment in its phase three trial; a remark on the treatment comparison in previously treated unresectable or metastatic cutaneous melanoma; a view on anticipated local trial access as another treatment option for advanced melanoma; a view on earlier tolerability evidence for investigational T-cell therapy in previously treated advanced melanoma.
- 2 more clinician views in the sources used in this report are not yet captured as evidence in this edition.
- 3 passages in 3 sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 37 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
Show all 15 known gaps +Fewer −
- Further source limits: 9 sources about other trials or topics are not included.
- The sources reviewed for this edition are a selected public discussion, not a representative HCP survey. Repeated statements and cross-platform posts cannot be counted as independent clinician agreement.
- Discussion without recognized trial or drug wording may be absent. Several possible passages were not fully assessed, and some earlier discussion and media relays are not represented; additional or historically earlier views may therefore be missing.
- Coverage of alternative investigational choices and account-level preferences is incomplete. The HLA-typing point and uveal-enrollment question alone do not describe those choices or preferences.
- No full SUPRAME protocol or exact-trial publication was available in the reviewed material to reconcile secondary amendment descriptions. Exact regulatory labeling for IMA203 and nivolumab plus relatlimab was also incomplete, limiting independent confirmation of authorized-use descriptions.
- The cited efficacy and safety observations concern earlier IMA203 studies, not randomized SUPRAME outcomes. Accounts describing a cutaneous-melanoma cohort, heavily refractory advanced melanoma or metastatic melanoma should not be pooled as if they described one population.
- Earlier accounts give different prior-treatment figures, response wording and IL-2 descriptions. Those differences remain unresolved rather than being silently harmonized, and the episode's unattributed IL-2 wording does not establish disagreement between named speakers.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- Relayed company announcements, analyst notes and a research note's interpretation of a KOL survey are not direct individual HCP testimony. Probabilities, comparative labels and survival benchmarks remain those sources' assessments.
- Activation accounts, eligibility descriptions and projected readout or filing dates retain their original timing. They do not establish present site availability, a current complete eligibility checklist or completed regulatory milestones.
How reports are built and checked: Methods.
Editions and corrections
Routine maintenance: 2 fixes (names, counts, text)
None of these changed a statement, finding or source.
- Nov 20, 2026 UTCThe trial's name is spelled as its investigators write it, “SUPRAME” (NCT06743126), outside quotations (was “SURPRAME”).
- Nov 20, 2026 UTCAn editorial bracket follows a transcription-garbled trial name in quotations: “SURPRAME [SUPRAME]”.
Last checked for new commentary Nov 20, 2026 UTC. No changes. Follow new editions and changes in this report's change feed (JSON Feed), or the catalog's. How versions and corrections work.
Cite this report
Erudio Health. SUPRAME (NCT06743126): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 20, 2026. https://www.erudio.com/reports/suprame-nct06743126
For your AI agent
Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.
Help me decide whether to buy the Erudio report "SUPRAME" (NCT06743126), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.
1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "suprame-nct06743126". If you cannot make requests, read https://www.erudio.com/reports/suprame-nct06743126.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email, my organization and the product: the current edition, or 3, 6 or 12 months of updates. Call create_order with report "NCT06743126", that product, email and organization, then show me the quote and the checkout_url to pay by card. If you have a wallet with a payment client for HTTP 402 (MPP with USDC on Tempo, or x402 with USDC on Base) and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id NCT06743126 and sections ["all"], and summarize the findings for me with their sources. The full report can be long: save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.
When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.Or read the record directly: JSON, Markdown or MCP
curl https://www.erudio.com/reports/suprame-nct06743126.json
curl https://www.erudio.com/reports/suprame-nct06743126.md
# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "suprame-nct06743126" })release 0a3613f9041f18b70fb00c03d7a922311a03ea6e570acd12d1897c4fae73659e
Questions
How much does the SUPRAME report cost?
One edition costs $750 (Focused · 108 verified statements · 56 from 9 confirmed clinicians). With updates: 3 months $1,300, 6 months $1,900, 12 months $2,600. Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.
What does the SUPRAME report cover?
108 statements from 39 sources (3 podcasts, 3 videos, 33 posts), 56 of them from 9 confirmed clinicians, each linked to its source. Commentary checked Nov 20, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.
Can my AI agent read or buy the SUPRAME report?
Yes. On https://mcp.erudio.com/free, with no sign-in, get_report_card({ "slug": "suprame-nct06743126" }) previews it and create_order({ "report": "suprame-nct06743126", "product": "edition", "buyer_email": "<work email>" }) orders it. Once paid, the license key reads it with read_report on https://mcp.erudio.com/mcp. Connect your AI client.
How current is the SUPRAME report?
Edition 1 (version 1.0.0), accepted Nov 20, 2026 UTC; last checked for new commentary Nov 20, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.